S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

Bibliographic Details
Main Authors:	S Banerjee, S Singhal, V Shah, R Van Vollenhoven, M Pike, E Morand, I Catlett, VP Werth, JT Merrill, N Delev, C Hobar, B Sharkey, T Wegman
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-10-01
Series:	Lupus Science and Medicine

Similar Items

P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial
by: Joseph F Merola, et al.
Published: (2024-03-01)

LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
by: Bindu Murthy, et al.
Published: (2023-07-01)

P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
by: Richard Furie, et al.
Published: (2024-03-01)

Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
by: Robert Roskoski, Jr.
Published: (2023-03-01)

O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus
by: Laura Geraldino-Pardilla, et al.
Published: (2024-03-01)

Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know?
by: Inês Pereira Amaral, et al.
Published: (2023-06-01)

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
by: Arianna Zhang, BS, et al.
Published: (2024-03-01)

TYK2 in Tumor Immunosurveillance
by: Anzhelika Karjalainen, et al.
Published: (2020-01-01)

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
by: Nicole Bouché, BS, et al.
Published: (2023-09-01)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
by: Ian M. Catlett, et al.
Published: (2023-01-01)

TYK2: An Upstream Kinase of STATs in Cancer
by: Katharina Wöss, et al.
Published: (2019-11-01)

LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
by: Chun Wu, et al.
Published: (2023-07-01)

TYK2 Variants in B-Acute Lymphoblastic Leukaemia
by: Edgar Turrubiartes-Martínez, et al.
Published: (2020-11-01)

TYK2 in Cancer Metastases: Genomic and Proteomic Discovery
by: Dana C. Borcherding, et al.
Published: (2021-08-01)

Tyk2 Targeting in Immune-Mediated Inflammatory Diseases
by: Lluís Rusiñol, et al.
Published: (2023-02-01)

Tyk2 is a tumor suppressor in colorectal cancer
by: Stefan Moritsch, et al.
Published: (2022-12-01)

A TYK2 Gene Mutation c.2395G>A Leads to TYK2 Deficiency: A Case Report and Literature Review
by: Peilin Wu, et al.
Published: (2020-05-01)

Deucravacitinib in the treatment of psoriasis
by: Tomás Estevinho, et al.
Published: (2023-12-01)

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
by: Dendrou, C, et al.
Published: (2016)

Functional characterization of NPM1–TYK2 fusion oncogene
by: Sudhakiranmayi Kuravi, et al.
Published: (2022-01-01)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
by: Shan Jing, et al.
Published: (2023-11-01)

Molecular Characteristics of TYK2 Gene Expressions in Patients with Colorectal Cancer
by: Zahra Mozooni, et al.
Published: (2023-01-01)

Targeting TYK2 alleviates Rab27A-induced malignant progression of non-small cell lung cancer via disrupting IFNα-TYK2-STAT-HSPA5 axis
by: Yuanyuan Zeng, et al.
Published: (2024-03-01)

Treatment of oral lichen planus using deucravacitinib
by: Mindy Vu, BS, et al.
Published: (2024-02-01)

Associations of genetic variants within TYK2 with pulmonary tuberculosis among Chinese population
by: Mingwu Zhang, et al.
Published: (2024-02-01)

Successful treatment of acrodermatitis continua of Hallopeau by TYK2 inhibitor with every other day
by: Yuji Kan, et al.
Published: (2024-12-01)

Use of TYK2 inhibitor to relieve reactive granulomatous dermatitis due to myelodysplastic syndrome
by: Christina Huang, BS, et al.
Published: (2023-10-01)

PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design
by: S Banerjee, et al.
Published: (2022-10-01)

Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene.
by: Dyment, D, et al.
Published: (2012)

Lack of association between TYK2 and STAT3 genes and Crohn’s disease in the Malaysian population
by: Lee, W.S., et al.
Published: (2013)

Lack of association between TYK2 and STAT3 genes and Crohn's disease in the Malaysian population
by: Lian, L.H., et al.
Published: (2013)

Mesenchymal stem cells alleviate psoriasis-like dermatitis in mice by inhibiting TYK2 phosphorylation
by: Lina LIANG, et al.
Published: (2022-06-01)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
by: Ana Martins, et al.
Published: (2023-05-01)

TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes
by: Keiichiro Mine, et al.
Published: (2024-02-01)

Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
by: Lise Torp Jensen, et al.
Published: (2023-11-01)

Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases
by: Zhiqin Fang, et al.
Published: (2023-11-01)

TYK2 correlates with immune infiltration: A prognostic marker for head and neck squamous cell carcinoma
by: Yaodong He, et al.
Published: (2022-12-01)

LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2
by: Richard A Furie, et al.
Published: (2023-07-01)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023-05-01)

A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways
by: Celia X.-J. Chen, et al.
Published: (2023-10-01)